Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

The selection of candidate vaccines for the STV involves evaluation of pre-defined criteria, including:

their safety and proven potential for effectiveness
stability of the vaccine
demonstration that they can be stored and transported easily under normal conditions
availability - whether they can be produced quickly for global distribution
the ease with which they can be given to individuals (how the vaccines are given, the number of doses etc)
To date the independent vaccine prioritization advisory group has reviewed the evidence generated on approximately 20 candidate vaccines. Of these, two candidate vaccines have been approved for inclusion in the STV. These are a spike adjuvanted vaccine developed by Medigen, and a DNA vaccine encoding the spike protein developed by Inovio.

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines

https://cdn.who.int/media/docs/default-source/blue-print/new2_solidarity-trial-vaccines-(stv)-presentation-4_final.pdf?sfvrsn=276fb250_18

Peruse Slide 26 of 44:

What ‘follow-up’ happens after the vaccines/
interventions are given?
Overview of the protocol visits and procedures
Main and secondary endpoints
Exploratory endpoints only
Visit number
1
2
3
4
5
6
7
Visit description
Vaccination dose 1
Follow-up visit days post-dose 1
Vaccination dose 2
Follow-up visit 7 days post-dose 2
Safety phone calls
Follow-up visit 180 days post-last dose
Follow-up visit 365 days post-last dose
Visit window (days)
Day 1
Day +7 (6-8) Post-dose 1
As per vaccine schedule
Day +7 (6-8) Post-dose 2
Day +7
(6-8) Post-previous contact – call
Day [phone] days) Post-last dose
Day [phone] days) Post-last dose